


MHI Begins Production and Marketing of Advanced Cancer Radiotherapy Machine

On January 22, Mitsubishi Heavy Industries, Ltd. (MHI) announced that it would begin the business of producing and marketing its highly advanced radiotherapy machine for cancer treatment in earnest, having obtained the necessary manufacturing and marketing licenses from the Japanese Ministry of Health, Labor and Welfare. The machine is capable of precisely identifying the location of tumors and targeting exactly through X-ray irradiation.

The new machine, called the MHI-TM2000 linear accelerator system, was developed by MHI in collaboration with Kyoto University and the Institute of Biomedical Research and Innovation in Kobe, supported by the New Energy and Industrial Technology Development Organization (NEDO). It incorporates an innovative gimbaled X-ray irradiation head with tilt and pan rotation functions -- the first-ever such device in the world -- that will enable fine adjustments in any direction. It is also equipped with two X-ray radiography devices that can show internal images of the body. Those features all allow the MHI-TM2000 to achieve the quick, pinpoint irradiation of a tumor. The X-ray generator incorporates a small-scale accelerating tube developed by NEDO, permitting a more compact configuration and freer mechanical movement than before.



MHI-TM2000

In October 2005, MHI established MHI Medical Systems, Inc. jointly with Konica Minolta Medical & Graphic, Inc., Mitsubishi Corporation and Seika Corporation in order to market the new machine and provide servicing for it. The company will soon launch full-scale marketing activities, having received the domestic license on January 16. Also, the machine previously received approval by the U.S. Food and Drug Administration (FDA). In overseas markets, MHI will cooperate with BrainLAB AG of Germany, supplying the machine on an original equipment manufacturing (OEM) basis.

Three years from now, MHI plans to expand the business to a scale of 10 billion yen (around \$93 million at \$1=107 yen) in annual sales. It will reinforce a plant devoted to radiotherapy machine production at its Hiroshima Machinery Works, with a yearly production capacity of 20 units.

Editor: Noriyuki Ishii, JAIF